Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 21

1.

Toward Standardization of Preanalytical Procedures for Cell-Free DNA Profiling.

Tsui DWY, Barnett E, Scher HI.

Clin Chem. 2019 Oct 31. pii: clinchem.2019.310854. doi: 10.1373/clinchem.2019.310854. [Epub ahead of print] No abstract available.

PMID:
31672861
2.

Tracking tumour evolution in glioma through liquid biopsies of cerebrospinal fluid.

Miller AM, Shah RH, Pentsova EI, Pourmaleki M, Briggs S, Distefano N, Zheng Y, Skakodub A, Mehta SA, Campos C, Hsieh WY, Selcuklu SD, Ling L, Meng F, Jing X, Samoila A, Bale TA, Tsui DWY, Grommes C, Viale A, Souweidane MM, Tabar V, Brennan CW, Reiner AS, Rosenblum M, Panageas KS, DeAngelis LM, Young RJ, Berger MF, Mellinghoff IK.

Nature. 2019 Jan;565(7741):654-658. doi: 10.1038/s41586-019-0882-3. Epub 2019 Jan 23.

3.

Measurement of Plasma Cell-Free Mitochondrial Tumor DNA Improves Detection of Glioblastoma in Patient-Derived Orthotopic Xenograft Models.

Mair R, Mouliere F, Smith CG, Chandrananda D, Gale D, Marass F, Tsui DWY, Massie CE, Wright AJ, Watts C, Rosenfeld N, Brindle KM.

Cancer Res. 2019 Jan 1;79(1):220-230. doi: 10.1158/0008-5472.CAN-18-0074. Epub 2018 Nov 2.

4.

Effects of Collection and Processing Procedures on Plasma Circulating Cell-Free DNA from Cancer Patients.

Risberg B, Tsui DWY, Biggs H, Ruiz-Valdepenas Martin de Almagro A, Dawson SJ, Hodgkin C, Jones L, Parkinson C, Piskorz A, Marass F, Chandrananda D, Moore E, Morris J, Plagnol V, Rosenfeld N, Caldas C, Brenton JD, Gale D.

J Mol Diagn. 2018 Nov;20(6):883-892. doi: 10.1016/j.jmoldx.2018.07.005. Epub 2018 Aug 28.

5.

Dynamics of multiple resistance mechanisms in plasma DNA during EGFR-targeted therapies in non-small cell lung cancer.

Tsui DWY, Murtaza M, Wong ASC, Rueda OM, Smith CG, Chandrananda D, Soo RA, Lim HL, Goh BC, Caldas C, Forshew T, Gale D, Liu W, Morris J, Marass F, Eisen T, Chin TM, Rosenfeld N.

EMBO Mol Med. 2018 Jun;10(6). pii: e7945. doi: 10.15252/emmm.201707945.

6.

Circulating cell-free DNA for non-invasive cancer management.

Stewart CM, Tsui DWY.

Cancer Genet. 2018 Dec;228-229:169-179. doi: 10.1016/j.cancergen.2018.02.005. Epub 2018 Mar 11. Review.

7.

Detection of somatic RAS mutations in circulating tumor DNA from metastatic colorectal cancer patients: are we ready for clinical use?

Montagut C, Tsui DW, Diaz LA Jr.

Ann Oncol. 2018 May 1;29(5):1083-1084. doi: 10.1093/annonc/mdy091. No abstract available.

PMID:
29554200
8.

The value of cell-free DNA for molecular pathology.

Stewart CM, Kothari PD, Mouliere F, Mair R, Somnay S, Benayed R, Zehir A, Weigelt B, Dawson SJ, Arcila ME, Berger MF, Tsui DW.

J Pathol. 2018 Apr;244(5):616-627. doi: 10.1002/path.5048. Epub 2018 Mar 12. Review.

9.

Excerpts from the 1st international NTNU symposium on current and future clinical biomarkers of cancer: innovation and implementation, June 16th and 17th 2016, Trondheim, Norway.

Robles AI, Olsen KS, Tsui DW, Georgoulias V, Creaney J, Dobra K, Vyberg M, Minato N, Anders RA, Børresen-Dale AL, Zhou J, Sætrom P, Nielsen BS, Kirschner MB, Krokan HE, Papadimitrakopoulou V, Tsamardinos I, Røe OD.

J Transl Med. 2016 Oct 19;14(1):295.

10.

Erratum: The somatic mutation profiles of 2,433 breast cancers refine their genomic and transcriptomic landscapes.

Pereira B, Chin SF, Rueda OM, Vollan HK, Provenzano E, Bardwell HA, Pugh M, Jones L, Russell R, Sammut SJ, Tsui DW, Liu B, Dawson SJ, Abraham J, Northen H, Peden JF, Mukherjee A, Turashvili G, Green AR, McKinney S, Oloumi A, Shah S, Rosenfeld N, Murphy L, Bentley DR, Ellis IO, Purushotham A, Pinder SE, Børresen-Dale AL, Earl HM, Pharoah PD, Ross MT, Aparicio S, Caldas C.

Nat Commun. 2016 Jun 6;7:11908. doi: 10.1038/ncomms11908. No abstract available.

11.

The somatic mutation profiles of 2,433 breast cancers refines their genomic and transcriptomic landscapes.

Pereira B, Chin SF, Rueda OM, Vollan HK, Provenzano E, Bardwell HA, Pugh M, Jones L, Russell R, Sammut SJ, Tsui DW, Liu B, Dawson SJ, Abraham J, Northen H, Peden JF, Mukherjee A, Turashvili G, Green AR, McKinney S, Oloumi A, Shah S, Rosenfeld N, Murphy L, Bentley DR, Ellis IO, Purushotham A, Pinder SE, Børresen-Dale AL, Earl HM, Pharoah PD, Ross MT, Aparicio S, Caldas C.

Nat Commun. 2016 May 10;7:11479. doi: 10.1038/ncomms11479.

12.

Profiling Non-Small Cell Lung Cancer: From Tumor to Blood.

Tsui DW, Berger MF.

Clin Cancer Res. 2016 Feb 15;22(4):790-2. doi: 10.1158/1078-0432.CCR-15-2514. Epub 2015 Dec 15.

13.

Multifocal clonal evolution characterized using circulating tumour DNA in a case of metastatic breast cancer.

Murtaza M, Dawson SJ, Pogrebniak K, Rueda OM, Provenzano E, Grant J, Chin SF, Tsui DWY, Marass F, Gale D, Ali HR, Shah P, Contente-Cuomo T, Farahani H, Shumansky K, Kingsbury Z, Humphray S, Bentley D, Shah SP, Wallis M, Rosenfeld N, Caldas C.

Nat Commun. 2015 Nov 4;6:8760. doi: 10.1038/ncomms9760.

14.

The translational potential of circulating tumour DNA in oncology.

Patel KM, Tsui DW.

Clin Biochem. 2015 Oct;48(15):957-61. doi: 10.1016/j.clinbiochem.2015.04.005. Epub 2015 Apr 15. Review.

PMID:
25889059
15.

EGFR exon 20 insertion A763-Y764insFQEA and response to erlotinib--Letter.

Voon PJ, Tsui DW, Rosenfeld N, Chin TM.

Mol Cancer Ther. 2013 Nov;12(11):2614-5. doi: 10.1158/1535-7163.MCT-13-0192. Epub 2013 Aug 22. No abstract available.

16.

Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA.

Murtaza M, Dawson SJ, Tsui DW, Gale D, Forshew T, Piskorz AM, Parkinson C, Chin SF, Kingsbury Z, Wong AS, Marass F, Humphray S, Hadfield J, Bentley D, Chin TM, Brenton JD, Caldas C, Rosenfeld N.

Nature. 2013 May 2;497(7447):108-12. doi: 10.1038/nature12065. Epub 2013 Apr 7.

PMID:
23563269
17.

Analysis of circulating tumor DNA to monitor metastatic breast cancer.

Dawson SJ, Tsui DW, Murtaza M, Biggs H, Rueda OM, Chin SF, Dunning MJ, Gale D, Forshew T, Mahler-Araujo B, Rajan S, Humphray S, Becq J, Halsall D, Wallis M, Bentley D, Caldas C, Rosenfeld N.

N Engl J Med. 2013 Mar 28;368(13):1199-209. doi: 10.1056/NEJMoa1213261. Epub 2013 Mar 13.

18.

Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA.

Forshew T, Murtaza M, Parkinson C, Gale D, Tsui DW, Kaper F, Dawson SJ, Piskorz AM, Jimenez-Linan M, Bentley D, Hadfield J, May AP, Caldas C, Brenton JD, Rosenfeld N.

Sci Transl Med. 2012 May 30;4(136):136ra68. doi: 10.1126/scitranslmed.3003726.

19.

Epigenetic approaches for the detection of fetal DNA in maternal plasma.

Tsui DW, Chiu RW, Lo YD.

Chimerism. 2010 Jul-Sep;1(1):30-5. doi: 10.4161/chim.1.1.12439.

20.

Systematic identification of placental epigenetic signatures for the noninvasive prenatal detection of Edwards syndrome.

Tsui DW, Lam YM, Lee WS, Leung TY, Lau TK, Lau ET, Tang MH, Akolekar R, Nicolaides KH, Chiu RW, Lo YM, Chim SS.

PLoS One. 2010 Nov 30;5(11):e15069. doi: 10.1371/journal.pone.0015069.

21.

Quantitative aberrations of hypermethylated RASSF1A gene sequences in maternal plasma in pre-eclampsia.

Tsui DW, Chan KC, Chim SS, Chan LW, Leung TY, Lau TK, Lo YM, Chiu RW.

Prenat Diagn. 2007 Dec;27(13):1212-8.

PMID:
17994635

Supplemental Content

Support Center